Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-03-02 @ 9:08 PM
Study NCT ID:
NCT01828034
Status:
COMPLETED
Last Update Posted:
2020-11-17
First Post:
2013-04-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Sponsor:
Organization:
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Time Perspective List:
Who Masked List: